目前,大多数随机临床研究排除了CKD 4~5期(eGFR<20ml/min/1.73㎡)患者,因此关于他们的治疗手段相对单一,仅有低蛋白饮食、血管紧张素转化酶抑制剂(ACEi)以及多学科综合治疗。然而,观察性研究提示,上述患者如果能将eGFR下降速率控制在2...
不过,对于SGLT-2i在晚期CKD患者(eGFR<30mL/min/1.73m^2)中的安全性和有效性仍知之甚少,而这些患者恰恰特别容易发生心血管事件和进行性肾功能衰竭。 相比之下,DAPA-CKD试验(达格列净)招募的受试者eGFR范围为25-75 mL/min/1.73m^2,...
The patients had a mean age of 67.5 years in the dapagliflozin group, and 71.4 in the integrated care group. About 34.2% and 45% were female in the two groups, respectively; the mean eGFR at baseline was about 19 mL/min/1.73 m2. Notably, 56 of the patients had stage 5 CKD. Patient...
2021年5月JASN上发表的一篇对DAPA-CKD的事后分析论文《Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease》对此问题进行了举证。 该分析选取DAPA-CKD研究中eGFR<30 mL/min/1.73m²的CKD-4期的受试者624人进行分析,在随访期中,观察该组中达格列净组和安慰剂组,该组和CKD2/3级组在主要复合终点事件...
1.Solis-JimenezF, Perez-Navarro LM, Cabrera-Barron R, et al. Effect of the combination ofbumetanide plus chlorthalidone on hypertension and volume overload in patientswith chronic kidney disease stage 4-5 KDIGO without renal replacement therapy:a double-blind randomized HEBE-CKD trial. BMC Nephrol...
In addition, stage-by-stage analysis has never been formally performed. METHODS. We analyzed data from the Chronic Kidney Disease Japan Cohort Study, which included a large proportion of patients with CKD stages 4 and 5. We estimated eGFR slopes over three evaluation periods (0.5, 1, and 2 ...
慢性肾脏病(chronic kidney disease,CKD)已成为世界性的公共健康问题,CKD患者最终会进展至终末期肾病(end stage renal disease,ESRD),需要长期依赖透析或肾移植维持生命,不仅严重降低患者的生活质量,也给社会和家庭带来了沉重的经济负担。 慢性肾脏病进入疾病的发展3期以后,已不能临床治愈,也就是普通大众理解的慢性肾衰...
关键词:滋肾降浊汤;脾肾气阴两虚夹瘀证;慢性肾脏病(CKD4期);FGF23;Klotho蛋白。 Abstract: Objective: To evaluate the clinical efficacy of Zishen Jiangzhuo Decoction on patients with spleen-kidney qi and yin deficiency syndrome complicated with stasis syndrome chronic kidney disease stage four (CKD4...
慢性肾脏病(chronic kidney disease,CKD)已成为世界性的公共健康问题,CKD患者最终会进展至终末期肾病(end stage renal disease,ESRD),需要长期依赖透析或肾移植维持生命,不仅严重降低患者的生活质量,也给社会和家庭带来了沉重的经济负担。 慢性肾脏病进入疾病的发展3期以后,已不能临床治愈,也就是普通大众理解的慢性肾衰...
大家要的正能量,2019年3月穿刺,出院3个月治疗,iga3-4级,牛津分型M1E0S1T0C2(按分型标准应该是C1,怀疑报告出错了),这是最新第三次复查结果,病友共勉。ckd2期到指标本月ckd1期,住院尿蛋白4066到167,肌酐110-120-109-94(上限104),血压住院130-190,目前75-110,,估算eGFR历次76-70-68-77-94,这个病都不...